As a primary care physician, how should I evaluate and manage a patient with fatigue, borderline low red blood cell count, low ferritin, mildly elevated high‑sensitivity C‑reactive protein, mildly elevated monocyte percentage, and normal anion gap, with all other labs normal?

Initiate Iron Supplementation Immediately

Your patient has iron deficiency (ferritin 34 ng/mL) with mild inflammation (hsCRP 4.3 mg/L), which is the most likely treatable cause of their worsening fatigue, and you should start oral iron supplementation now while conducting a focused evaluation for underlying causes.

Understanding the Clinical Picture

Your patient presents with:

• Low ferritin (34 ng/mL): This indicates depleted iron stores. While the British Society of Gastroenterology guidelines 1 note that ferritin <30 ng/mL typically indicates iron deficiency in healthy individuals, your patient has mild inflammation (hsCRP 4.3), which can falsely elevate ferritin. In the presence of inflammation, ferritin up to 100 ng/mL may still represent true iron deficiency 2.
• Mild inflammation (hsCRP 4.3): This modest elevation suggests either subclinical inflammatory process or the anemia of chronic disease (ACD) coexisting with iron deficiency 3.
• Borderline low RBC (4.1): While not overtly anemic by WHO criteria, this combined with low ferritin and fatigue warrants intervention.
• Elevated monocytes (9.1%): May reflect chronic inflammation but is nonspecific.

Immediate Management Steps

1. Start Iron Supplementation Without Delay

Begin oral iron therapy immediately 4:

• Ferrous sulfate 325 mg (65 mg elemental iron) once daily, taken on an empty stomach if tolerated, or with food if GI side effects occur
• Alternative formulations (ferrous fumarate, ferrous gluconate, or ferrous bisglycinate) if patient experiences intolerance
• Consider adding vitamin C 500 mg to enhance absorption 4
• Target ferritin >100 ng/mL for symptom resolution 3

2. Conduct Focused Evaluation for Underlying Causes

Critical history to obtain:

• Menstrual history (if premenopausal woman): Heavy or prolonged periods are the most common cause
• GI symptoms: Any abdominal pain, change in bowel habits, blood in stool, or dyspepsia
• Dietary assessment: Vegetarian/vegan diet, restrictive eating
• Medication review: NSAIDs, anticoagulants, aspirin (chronic GI blood loss)
• Family history: GI malignancy, celiac disease, inflammatory bowel disease

Essential additional testing:

• Celiac serology (IgA tissue transglutaminase): Only 3.2% requested in primary care fatigue workups 5, but critical given malabsorption potential
• H. pylori testing (non-invasive stool antigen or breath test): Can cause iron deficiency through chronic gastritis 6
• Stool for occult blood (if any GI symptoms or risk factors)

3. Determine Need for GI Investigation

Proceed with bidirectional endoscopy if:

• Male patient of any age with iron deficiency 6
• Postmenopausal woman with iron deficiency 6
• Premenopausal woman with GI symptoms, family history of GI malignancy, or failed iron supplementation trial 6
• Any patient with positive celiac serology or H. pylori requiring confirmation

Common pitfall to avoid: The AGA guidelines 6 note that premenopausal women without GI symptoms may reasonably defer endoscopy and trial iron supplementation first, but this assumes menstrual blood loss is the likely cause. If your patient has no clear menstrual explanation or fails to respond to iron, endoscopy becomes necessary.

Address Other Fatigue Contributors

While treating iron deficiency, simultaneously evaluate and manage:

Assess for Additional Deficiencies

The IBD fatigue guidelines 7 recommend checking:

• Vitamin B12 and folate: Especially if MCV trends upward
• Vitamin D: High prevalence of deficiency in fatigue
• Thyroid function (TSH): Should already be checked per standard fatigue workup 8

Evaluate Sleep Quality

• Use validated Pittsburgh Sleep Quality Index 7
• Sleep disturbance strongly correlates with fatigue and may worsen inflammatory markers 7

Screen for Mood Disorders

• Depression and anxiety are common contributors to fatigue 8
• Consider PHQ-9 or GAD-7 screening tools
• Low socioeconomic status and young age increase risk 8

Follow-Up Strategy

At 4-6 weeks:

• Recheck CBC, ferritin, and hsCRP
• Assess symptom improvement and medication tolerance
• If ferritin remains <100 ng/mL or symptoms persist, consider IV iron (especially if oral intolerance or malabsorption) 4

At 3 months:

• Confirm ferritin >100 ng/mL and hemoglobin normalization
• If no improvement despite adequate iron repletion, reconsider diagnosis and investigate for occult inflammation or other causes 7

Key Clinical Reasoning

The combination of low ferritin (34 ng/mL) with mild inflammation (hsCRP 4.3) most likely represents iron deficiency with early ACD 3. The European consensus 2 specifically addresses this scenario: when ferritin is 30-100 ng/mL with inflammation present, iron deficiency is likely. Your patient's worsening fatigue over the past month suggests progressive iron depletion affecting tissue function beyond just hemoglobin synthesis.

The elevated monocyte percentage (9.1%) warrants attention but should not delay iron therapy. While it may indicate chronic inflammation, isolated monocytosis without other concerning features (weight loss, fever, lymphadenopathy) does not require immediate extensive workup. Monitor this with repeat CBC after iron repletion.

The normal anion gap (7.0) is reassuring and argues against metabolic acidosis or renal tubular acidosis as fatigue contributors. The "arachoidionic acid 7.4" likely refers to a different parameter (possibly misreported); clarify this value but it should not alter your immediate management plan.